Baxter International Inc. (BAX) announced the U.S. FDA approval of new formulations of Clinimix Injections and Clinimix E Injections with higher protein for patients requiring parenteral nutrition. These new Clinimix formulations contain up to 80 g/L of amino acids, the highest protein in any multi-chamber bag available in the U.S.

Create Account

Dark

chart

exchange

Check out our Level2View

Baxter International Inc. (BAX) announced the U.S. FDA approval of new formulations of Clinimix Injections and Clinimix E Injections with higher protein for patients requiring parenteral nutrition. These new Clinimix formulations contain up to 80 g/L of amino acids, the highest protein in any multi-chamber bag available in the U.S.

RTTNews | Sep 23, 2020 08:23AM EDT

08:22 Wednesday, September 23, 2020 (RTTNews.com) - Baxter International Inc. (BAX) announced the U.S. FDA approval of new formulations of Clinimix Injections and Clinimix E Injections with higher protein for patients requiring parenteral nutrition. These new Clinimix formulations contain up to 80 g/L of amino acids, the highest protein in any multi-chamber bag available in the U.S.

"The introduction of Clinimix and Clinimix E formulations offers the highest protein in a multi-chamber bag in the U.S., allowing clinicians more flexibility in meeting their patients' nutritional goals," said Heather Knight, general manager of Baxter's U.S. hospital products business.

Read the original article on RTTNews ( https://www.rttnews.com/3130872/baxter-announces-fda-approval-of-clinimix-and-clinimix-e-injections.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved